Delta, Kelowna, BC – September 24, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 472 (NASDAQ: NEPT) (TSXV: NUMI) (CSE: BAMM) (CSE: CURA) (TSX: IN)
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com “Potcast” featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
Today’s podcast is sponsored by Cannabis Suisse Corp. ( OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company’s facilities for producing cannabis are based in Dietikon, Switzerland, and contain the art surveillance equipment to enable an around the clock webcast. Cannabis Suisse grows high quality, organic cannabis with sustainable, all-natural principles. The Company’s products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse proprietary trademarked MoldStandard is a quantitative microbiology method for analyzing yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary trademarked CannaMec is a method for quantifying and removing residual solvents during packaging and storage of CBD products. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
In today’s podcast we look at a few public announcements.
Neptune Wellness Solutions Inc. ( NASDAQ: NEPT ) ( TSX: NEPT ) announced entering into an agreement with the British Columbia Liquor Distribution Branch (BCLDB), the wholesaler and public retailer of non-medical cannabis throughout the province, for the sale and distribution of Neptune’s new proprietary Mood Ring product line.
“We are pleased to be partnering with BCLDB to bring Mood Ring to the province of British Columbia. This will allow Neptune to bring the benefits of legal cannabis to a larger group of people,” said Michael Cammarata, Chief Executive Officer and President of Neptune.
The agreement marks the launch of Neptune’s Mood Ring product line for sale into the Canadian non-medical cannabis market. Products are expected to be available for purchase this fall through the BC Cannabis Store online, in addition to its 20 government-run retail locations across British Columbia. Additionally, the Mood Ring product line will be available to the 271 private licensed retailers in British Columbia.
The initial product rollout will include Mood Ring’s High CBD products and Mood Ring’s Classic Hashish and Legacy Hashish. Mood Ring will deliver sustainable and premium CBD and THC products to the non-medical cannabis market.
Mood Ring will use Neptune’s proprietary cold ethanol extraction process technology to create full spectrum extracts for the Company’s CBD products and newly implemented solventless extraction for THC concentrates.
Numinus Wellness Inc. ( TSXV: NUMI ), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, announced that it has begun cultivating Psilocybe mushrooms, for the purpose of psilocybin production, at its 7000 square-foot Health Canada licensed facility. Psilocybin-assisted psychotherapy is currently being studied as a treatment for a range of mental health conditions including depression, anxiety, and substance use disorders.
Under its Health Canada licence for the production and extraction of psilocybin from mushrooms, Numinus intends to cultivate and harvest the mushrooms for a variety of purposes including:
- development of standardized extraction methods
- exploration of product formulations of naturally occurring psilocybin
- development and evaluation of qualitative and quantitative mycochemicals standardized test methodologies
- exploration of the ability to investigate naturally occurring psilocybin’s efficacy as an alternative supply to synthetic psilocybin currently used in research
- ultimately, the delivery of safe, evidence-based psilocybin-assisted psychotherapy at clinics including its own
“We are thrilled to start growing mushrooms at our laboratory under our Health Canada licence,” says Michael Tan, Chief Operating Officer. “We envision a day when the option of natural, plant-based psilocybin is available for use in therapies at Numinus Clinics and by others, and this is a tangible step towards that goal.”
Numinus’ vertically integrated ecosystem positions the Company to be a first-in-market, trusted leader in the delivery of psychedelic-assisted psychotherapies when regulated. From product development and supply, to analytics and testing, to clinical protocol development and implementation science in partnership with leading research organizations, the ecosystem approach allows Numinus to ensure quality control and best-in-class delivery with steady revenue streams to support its developments.
Body and Mind Inc. ( CSE: BAMM ) ( OTCQB: BMMJ ), a debt free multi-state operator focused on limited license markets, announced the launch of Pretzel Bites into the California market and engagement of Harbor Access LLC for investor relations services.
“We are excited to expand our California branded product portfolio with the addition of our popular Pretzel Bites edibles,” stated Michael Mills, CEO of Body and Mind. “We have been selling Pretzel Bites in the Nevada market with strong customer feedback and special releases including Fourth of July and Electric Circus drops. We feel Pretzel Bites are a timely addition to the expanding California market of new and cannacurious consumers who are seeking tested, tasty alternatives to inhaled consumption. Our pretzel bites each contain 10mg of THC distillate in butter caramel squeezed between salted pretzels and dipped in milk chocolate. Pretzel bites add to our expanding California branded product portfolio, which includes BaM Stix prerolls, Body and Mind preroll packs, distillate and live-resin cartridges, G-Pen cartridges and concentrates including live resin, shatter and wax.”
Curaleaf Holdings, Inc. ( CSE: CURA ) ( OTCQX: CURLF ) announced that its Select brand is launching a vape pen in collaboration with Belushi’s Farm, available exclusively in Oregon. Select, America’s #1 Cannabis Oil Brand, will release the limited-edition product with the famous Captain Jack’s strain, grown exclusively on Belushi’s Farm and featured in the new reality series GROWING BELUSHI on The Discovery Channel. The Captain Jack’s x Select strain will premiere at Curaleaf’s Portland dispensary and will also be available at selected dispensaries throughout Oregon.
Jack Murtha, known as “Captain Jack,” is a pioneer of cannabis cultivation who spent more than 40 years perfecting his namesake strain, based on Gulzar Afghanica, which he first encountered in 1971 during a hot summer in the valley of the Kush Mountains in Afghanistan. Learning the Afghani process for cultivating the plant, Captain Jack was gifted seeds by the village elders and he’s been growing the pure landrace strain from seed to flower ever since.
“After working to perfect his strain, which has roots in Afghanistan’s 4,000-year-old traditions, Captain Jack is working with Belushi’s Farm and Select to turn this legendary strain into oil,” said Jim Belushi. “This strain has never been tweaked in a laboratory or compromised, making it a perfect match for Select’s unparalleled quality. And, I can say it’s likely it has inspired many historic comedy sketches throughout the mid to late ’70s. Thanks to its long and storied history in the halls and offices of 30 Rock, we call Captain Jack’s strain ‘the Smell of SNL.'”
The Captain Jack’s x Select vape pen will be available in limited quantities now available at Curaleaf’s Portland dispensary. As the only Captain Jack product on the market, this partnership is the only way consumers can currently experience the high-quality oil they expect from Select with the creative power of the Captain Jack’s strain.
“Our goal with Select is to put the consumer first and deliver the best possible experience with full flavor and a smooth feel – without sacrificing on high quality control standards and superior testing standards,” said Joe Bayern, President at Curaleaf. “Jim holds the same high-quality approach at his farm, making this partnership a perfect pairing, and with the creativity and legacy behind the Captain Jack’s strain, we’re able to provide a product we know Oregonians will love.”
The launch of the Captain Jack’s x Select vape pen comes on the heels of Belushi’s new Discovery Channel television show, GROWING BELUSHI, which gives viewers a peek behind the curtain of the Belushi’s Farm operations in Oregon. This month, Belushi launched a limited-edition Blues Brothers x Grassroots flower in the Bubba Diagonal strain, available exclusively in Chicago. In July 2020, Curaleaf closed on its acquisition of Grassroots, giving the company the opportunity to continue developing innovative products and serving communities across the United States.
In response to the ongoing wildfires that have devastated Southern Oregon and displaced more than 42,000 residents, Curaleaf Oregon, Select, Jim Belushi and Belushi’s Farm have joined forces with a coalition of local cannabis companies to create the Jackson County Fire Relief Fund. Together, the coalition has pledged to raise $420,000 for the United Way of Jackson County, where funds will support the recovery of those affected in Jackson County, home to many of Oregon’s premier cannabis and hemp companies.
The Select brand was founded in Portland, Oregon and in February 2020 the brand was acquired by leading multi-state-operator Curaleaf. The company continues to roll out new products to serve the Oregon community, most recently with the launch of Select Elite Live, a high quality, high potency oil that offers a wide variety of strain-specific flavor and effects. Select products are available at Curaleaf Portland and in dispensaries state-wide. To find a dispensary near you that carries Select products, go to www.selectbetter.com and click “Find Us” for an interactive map of locations.
InMed Pharmaceuticals Inc. ( TSX: IN ) ( OTCQX: IMLFF ), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced that all subjects participating in its second Phase 1 clinical trial with INM-755 have completed treatment. INM-755 is being developed as a topical CBN-based cream to potentially treat Epidermolysis Bullosa (“EB”) as well as potentially other dermatological diseases.
The 755-102-HV clinical trial is a randomized, double-blind, vehicle-controlled, Phase 1 study designed to evaluate the safety and tolerability of INM-755 cream applied daily on epidermal wounds in healthy volunteers. Eight adult subjects were treated with two strengths of INM-755 cream over a 14-day treatment period. As with InMed’s first Phase 1 clinical trial with INM-755, the 755-102-HV trial is being conducted at the Centre for Human Drug Research in Leiden, the Netherlands.
Despite the COVID-19 pandemic and the resulting restrictions that have affected clinical development programs worldwide, the full treatment phase of this second Phase 1 trial was achieved with only a modest delay to the original timeline. With completion of both the 755-101-HV and the 755-102-HV treatment phases, and assuming positive safety and tolerability data of INM-755 on both intact skin and epidermal wounds, the Company will be better positioned to advance detailed planning for the first efficacy trial in EB patients.
InMed anticipates reporting results from both Phase 1 trials in the second half of calendar 2020 and, assuming a positive safety profile for INM-755, submitting regulatory filings for the first efficacy trial in EB patients in early 2021.
Once again, today’s podcast is sponsored by Cannabis Suisse Corp. ( OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company’s products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/ .
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com – News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns: Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Disclosure: Cannabis Suisse Corp. ( OTC: CSUI ), is a paid featured company on Investorideas.com
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Cannabis Social Media
Download our Mobile App for iPhone and Android
This article is for the purposes of solicitation subscriptions for this website. This website expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. This website or it’s authors do not own any shares of Cannabis Suisse Corp (CSUI) and does not buy, sell, or trade any shares of (CSUI). This article does not provide a professional analysis of a (CSUI) financial position. (CSUI) financial position and all other information regarding the featured Company should be verified directly with (CSUI). Please read our full disclaimer for more detailed information.